


Add-On Treatment with Pipamperon 8-12 (mean 9) mg (bid) after Treatment with Citalopram 10-20 (mean 30) mg (bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17 Totalscore = 29 at Baseline in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000

BEST AVAILABLE COPY

Figure 1

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (duloxetine) in MAJOR DEPRESSION





Figure 2

REMISSION RATES (HDRS-17 ≤ 7): COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (venlafaxine) vs SSRI's vs PLACEBO in MAJOR DEPRESSION




COMBO PIPAMPERON AS ADD-ON - CITALOPRAM WITH PIPAMPERON 8-12mg/day (mean 9mg/day) 20-60 (mean 33) days after the treatment with the SSRI (n=5)
SNRI Venlafaxine - Meta-analysis of Thase et al, Br J Psychiatry 2001; 178: 234-241
SSRI's - Meta-analysis of Thase et al, Br J Psychiatry 2001; 178: 234-241
PLACEBO - Meta-analysis of Thase et al, Br J Psychiatry 2001; 178: 234-241

Figure 3

Foregoing Treatment During 1-5 (mean 4) days with Pipamperon 8-12 (mean 10) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-50 (mean 26) mg/day (bid) (PICIT FG 1-5) in MDD (HDRS-17 at BL = 23) in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000)

Figure 4

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION




Figure 5

REMISSION RATES (HDRS-17 ≤ 7): COMBO PIPAMPERON-CITALOPRAM WITH AFORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (venlafaxine) in MAJOR DEPRESSION





Figure 6

Foregoing Treatment During 6-8 (mean 7) days with Pipamperon 8-12 (mean 11) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-40 (mean 30) mg/day (bid) (PICIT FG 6-8) in MDD (HDRS-17 at BL = 28 in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD




A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000

BEST AVAILABLE COPY

Figure 7

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 7 DAYS WITH PIPAMPERON 11mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION




COMBO PIPAMPERON-
CITALOPRAM WITH PIPAMPERON 8-
12 (mean 11) mg/day (bid) 6-8
(mean 7) days before treatment
with the SSRI (n=3)

DULOXETINE 40-120 mg/day
(n=152) (Goldstein et al. J. Clin.
Psychiatry (in press))

Figure 8

Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



* A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical

Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57, APR 2000)

BEST AVAILABLE COPY

Figure 9

HDRS-17 CHANGE FROM BASELINE: Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI duloxetine in MAJOR DEPRESSION




Figure 10

REMISSION RATES (HDRS-17 ≤ 7): Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI venlafaxine in MAJOR DEPRESSION




Figure 11

**Y-BOCS TOTALSCORE: Foregoing & Add-On Treatment with
Pipamperon 8-16 mg/day (bid) and Citalopram 30-80 mg/day (bid)
in comparison with the SSRI fluvoxamine in OCD**




Figure 12

**Y-BOCS OBSESSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**





Figure 13

Y-BOCS COMPULSION SCORE: Foregoing & Add-On Treatment with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day (bid) in comparison with the SSRI fluvoxamine in OCD




BEST AVAILABLE COPY

Figure 14

CGI-SEVERITY SCORE: Foregoing & Add-On Treatment with Pipamperon 8 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the

SSRI in Panic Disorder



○ Paroxetine in the treatment of panic disorder, Journal of Clinical Psychiatry 65: 405-413, No. 3, Mar 2004

★ COMBO PIPAMPERON-CITALOPRAM (n=3)

● Sertraline in the treatment of panic disorder, Journal of Clinical Psychiatry 65: 405-413, No. 3, Mar 2004

BEST AVAILABLE COPY

Figure 15